drugset / Trial / NCT00621361
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-08
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | — | Oral |
| Comparator | Cisplatin | Other / unclassified | — | Intravenous |
| Comparator | Etoposide | Small molecule | — | Intravenous |